Tag Archives: ALPHA

FDA to Potentially Clear ALLO-501A’s Pivotal Study in Q3 2022; Nirogacestat Combo Deprioritized; Data from ALLO-316 Delayed to 2023; Allogene Q2 2022 Earnings Call Summary

On Tuesday, August 9, Allogene held their Q2 2022 earnings call (press release) highlighting an anticipated FDA clearance of ALLO-501A’s (allogeneic CD19 CAR-T) pivotal trial in ≥3L DLBCL, while announcing the deprioritization of ALLO-715’s (allogeneic BCMA CAR-T) combination with nirogacestat. Of note, no major updates were presented from ALLO-316’s (allogeneic CD70 CAR-T) clinical development. Below, Celltelligence provides insights on how Allogene could accelerate ALLO-501A’s regulatory pathway, while discussing Allogene’s upcoming clinical updates.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Allogene ALLO-501 Ph1 ALPHA Results and ASCO 2020 Investor Call Summary

On Friday, May 29, Allogene held an investor call (press release), highlighting updated clinical data from the ALLO-501 (CD19 allogeneic CAR-T) Ph1 ALPHA study, in ≥3L NHL (DLBCL or FL). The data was also presented at ASCO 2020 (Sattva Neelapu et al, May 2020). Below, FENIX provides thoughts on the promising positive data from the ALPHA study, and particularly how ALLO-501 compares to equivalent autologous CD19 CAR-Ts from Novartis (Kymriah), Gilead (Yescarta), and BMS (liso-cel).

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.